Manager, Analytical Development
Guohong Zhao has served as Manager of Analytical Development of Tioga Research since September 2019. He has a broad background in analytical and physical chemistry and biochemistry, with over twenty-five years of experience in analytical method development for various products, including food and personal care products, by using variety of modern mass spectrometric techniques (LC-MS/MS, LC/TOF, GC-MS, FTMS, LDI-MS) and chromatographic techniques (HPLC, GC). Guohong has a PhD in Physical Chemistry from Swiss Federal Institute of Technology, Lausanne, Switzerland where his doctoral research focused on studying photodissociation and ion-molecule reactions of isomeric ions by using Fourier Transform Mass Spectrometry (also called Ion Cyclotron Resonance Mass Spectrometry). He then pursued post-doctoral research in the Environmental Analytical Research Laboratory of Texas A&M University at Galveston. He helped establish and managed an analytical laboratory to support clinical metabolism studies while working as a research scientist in Washington University School of Medicine in St. Louis. He joined Unilever as Senior Research Scientist to support formulation development and manufacturing processes for both hair care and deodorant products. Moving to Northland Laboratories (acquired by Matrix Science in 2018) in 2007, he was responsible for analytical method development and validation, problem solving in food testing, and technical reviews and approvals of laboratory daily operations. He has been a member of the American Chemical Society and the American Society for Mass Spectrometry since 1994 and was previously a member of AOAC and IFT.
Edward T. Kisak has served as CSO of Tioga Research since its founding. He has over twenty years of experience in topical formulation development, having served in both managerial and lead scientist roles. Ed has a PhD in Chemical Engineering from the University of California, Santa Barbara where his doctoral research focused on developing “vesosomes” – a multiplexed liposomal structure containing liposomes nested within other liposomes for advanced drug delivery therapies. This doctoral research was later pursued by Advanced Encapsulation – a start-up company co-founded by Ed to improve and develop the vesosome technology. Ed also served as consultant to Sinus Pharmaceuticals and reformulated their lead tobramycin sinusitis formulation, which later went on to clinical trials. After joining fqubed (later acquired by Nuvo Research, CA:NRI) in 2005, Ed acted as Director of Research, and was responsible for laboratory operations and for managing formulation innovation and skin delivery screening campaigns. During this tenure, Ed acted as the lead formulation scientist on developing PENNSAID® 2% (currently approved in the US for the treatment of osteoarthritis) along with other formulations in Nuvo’s pipeline. Additionally, he was the prime driving force behind the development, optimization and production-mode use of Tioga Research’s HTE platforms, including INSIGHT™, STORM™, SPATE™, SPLASH™, TORNADO™, MONSOON™ and SKIVER™.
There are many variations of passages of Lorem Ipsum avagtilable, but the majority have suffered alteration in some form, by injected hudfdfmour, or randomised words which don't look
There are many variations of passages of Lorem Ipsum avagtilable, but the majority have suffered alteration in some form